Relationships between plasma fibrinogen and prognosis and tumor metastasis in patients with nasopharyngeal carcinoma

doi:10.3760/cma.j.issn.1673-422X.2018.12.003

Abstract

Abstract: ObjectiveTo investigate the relationships between the plasma fibrinogen level before treatment and prognosis and tumor metastasis in patients with nasopharyngeal carcinoma. MethodsThe clinical data of 817 patients with nondistant metastasis nasopharyngeal carcinoma from January 2005 to October 2014 in our hospital were collected. All the patients were followed up, and the median followup time was 37.6 months. The critical value of plasma fibrinogen before treatment was determined by receiver operating characteristic (ROC) curve. The overall survival (OS) and distant metastasis free survival (DMFS) and their relevant factors were analyzed by KaplanMeier and Cox regression model. ResultsThe critical value of plasma fibrinogen before treatment was 3.314 g/L determined by ROC curve analysis. The plasma fibrinogen level before treatment was related to the TNM stage (χ2=6.048, P=0.014), T stage (χ2=13.764, P＜0.001) and distant metastasis after treatment (χ2=14.637, P<0.001). Survival analysis showed that the 3year OS rate and 3year DMFS rate in patients with plasma fibrinogen level ≥3.314 g/L before treatment were significantly lower than those in patients with plasma fibrinogen level ＜3.314 g/L, with significant differences (87.2% vs. 95.6%, χ2=4.562, P<0.001; 71.1% vs. 82.2%, χ2=5.153, P<0.001). Cox multivariate analysis showed that high level of plasma fibrinogen before treatment (HR=1.961, 95%CI: 1.3322.917, P=0.001), EB virus DNA (HR=1.929, 95%CI: 1.2752.849, P=0.001) and pretreatment stage (HR=1.653, 95%CI: 1.0132.709, P=0.045) were the independent influencing factors of OS. The high level of plasma fibrinogen before treatment (HR=1.519, 95%CI: 1.1421.964, P=0.002) and EB virus DNA (HR=1.950, 95%CI: 1.4832.555, P＜0.001) were the independent influencing factors of DMFS. Of the 817 patients, 179 patients (21.91%) had metastasis during the followup period, and 159 patients (88.83%) had metastasis within 3 years after treatment. The plasma fibrinogen level before treatment in 638 patients without metastasis (3.197±1.009) was significantly lower than that in 179 patients with metastasis (3.351±1.042; t=5.089, P=0.024), and was significantly lower than that in 87 patients with bone metastasis (3.430±1.004; t=6.752, P=0.009), 68 patients with pulmonary metastasis (3.301±1.018; t=4.281, P=0.039) and 71 patients with liver metastasis (3.413±1.107; t=6.398, P=0.011). ConclusionThe plasma fibrinogen level before treatment can be used as an independent index to predict the prognosis of patients with nasopharyngeal carcinoma, which is related to tumor metastasis.

Key words: Fibrinogen, Nasopharyngeal neoplasms, Metastasis, Prognosis

Yuan Haozhan, Ji Mingan, Wang Yanting. Relationships between plasma fibrinogen and prognosis and tumor metastasis in patients with nasopharyngeal carcinoma[J]. Journal of International Oncology, 2018, 45(12): 716-720.

References

［1］ Chen W, Zheng R, Zhang S, et al. Report of cancer incidence and mortality in China, 2010［J］. Ann Transl Med, 2014, 2(7): 61. DOI: 10.3978/j.issn.23055839.2014.04.05. ［2］ Huang TR, Zhang SW, Chen WQ, et al. Trends in nasopharyngeal carcinoma mortality in China, 19732005［J］. Asian Pac J Cancer Prev, 2012, 13(6): 24952502. ［3］ Xu ZJ, Zheng RS, Zhang SW, et al. Nasopharyngeal carcinoma incidence and mortality in China in 2009［J］. Chin J Cancer, 2013, 32(8): 453460. DOI: 10.5732/cjc.013.10118. ［4］ Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China［J］. Chin J Cancer, 2011, 30(2): 114119. ［5］ Xu ZX, Lin ZX, Fang JY, et al. Mortality characteristic and prediction of nasopharyngeal carcinoma in China from 1991 to 2013［J］. Asian Pac J Cancer Prev, 2015, 16(15): 67296734. ［6］毛承刚, 万俐佳, 沈敏, 等. 鼻咽癌治疗后生存率和预后总结与分析［J］. 中国耳鼻咽喉颅底外科杂志, 2015, 21(5): 386389. DOI: 10.11798/j.issn.10071520.201505009. ［7］刘宇, 杨澎, 田晓波, 等. 胃癌患者肿瘤恶性程度与凝血功能的相关性研究［J］. 中国医学装备, 2017, 14(6): 8992. DOI: 10.3969/J.ISSN.16728270.2017.06.025. ［8］徐建华. 胃癌术后凝血功能对患者生存率的影响［J］. 基层医学论坛, 2012, 16(4): 450452. ［9］胥芸芸, 翟振兴, 李桂香. 血浆纤维蛋白表达水平与肾细胞癌风险相关性的Meta分析［J］. 中国循证医学杂志, 2017, 17(5): 529535. DOI: 10.7507/16722531.201606076. ［10］张礼, 燕锦. 血浆纤维蛋白原在结直肠癌中的研究进展［J］. 肿瘤预防与治疗, 2016, 29(4): 231234. DOI: 10.3969/j.issn.16740904.2016.04.009. ［11］韩宇, 赵隽. 血浆纤维蛋白原在恶性肿瘤中的研究进展［J］. 中国医学创新, 2013, 10(27): 162164. DOI: 10.3969/j.issn.16744985.2013.27.075. ［12］ Gooi Z, Fakhry C, Goldenberg D, et al. AHNS series: do you know your guidelines? Principles of radiation therapy for head and neck cancer: a review of the National Comprehensive Cancer Network guidelines［J］. Head Neck, 2016, 38(7): 987992. DOI: 10.1002/hed.24448. ［13］ Chen A, Lee N, Yang C, et al. Comparison of intensitymodulated radiotherapy using helical tomotherapy and segmental multileaf collimatorbased techniques for nasopharyngeal carcinoma: dosimetric analysis incorporating quality assurance guidelines from RTOG 0225［J］. Technol Cancer Res Treat, 2010, 9(3): 291298. DOI: 10.1177/153303461000900308. ［14］ Lan M, Chen C, Huang Y, et al. Elevated plasma fibrinogen level shows superior prognostic value than EpsteinBarr virus DNA load for stage ⅣA/B nasopharyngeal carcinoma patients in the intensitymodulated radiotherapy era［J］. Oncotarget, 2016, 7(29): 4624246252. DOI: 10.18632/oncotarget.10083. ［15］罗晚媛, 唐莹, 何本夫. 血浆EBVDNA表达水平与鼻咽癌分期的相关性分析［J］. 实用癌症杂志, 2015, 30(8): 11161118. DOI: 10.3969/j.issn.10015930.2015.08.003. ［16］盖秀娟, 魏玉梅, 李宝生. 鼻咽癌预后相关因素研究进展［J］. 中华肿瘤防治杂志, 2016， 23(20): 13981402. DOI:10.16073/j.cnki.cjcpt.2016.20.011. ［17］ Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancerspecific, metastasisfree, as well as overall survival in a European cohort of nonmetastatic renal cell carcinoma patients［J］. Br J Cancer, 2013, 109(5): 11231129. DOI: 10.1038/bjc.2013.443. ［18］韩晓娜, 孙振强, 唐勇, 等. 结肠癌术前血浆纤维蛋白原水平与临床病理特征的关系［J］. 肿瘤防治研究, 2014, 41(12): 13261329. DOI: 10.3971/j.issn.10008578.2014.12.016. ［19］ Gao J, Zhang HY, Xia YF. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma［J］. Tumour Biol, 2013, 34(1): 3945. DOI: 10.1007/s132770120508y.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[8]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[9]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[10]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[13]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[14]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[15]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.